Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.
about
New and emerging disease modifying therapies for multiple sclerosisThe crystal structure of Lactococcus lactis dihydroorotate dehydrogenase A complexed with the enzyme reaction product throws light on its enzymatic functionLeflunomide: mode of action in the treatment of rheumatoid arthritisRegulation of STATs by polycystin-1 and their role in polycystic kidney diseaseHigh-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases.Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism.Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.Kynurenine pathway metabolites in humans: disease and healthy States.Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease.Purine and pyrimidine pathways as targets in Plasmodium falciparum.Leflunomide: long-term clinical experience and new uses.Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomideAHR-mediated immunomodulation: the role of altered gene transcription.Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.Leflunomide in renal transplantation.Treatment of multiple sclerosis: current concepts and future perspectives.Leflunomide: an immunosuppressive drug with multiple effects on T cell function.Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosisThe mammalian homologue of Prp16p is overexpressed in a cell line tolerant to Leflunomide, a new immunoregulatory drug effective against rheumatoid arthritis.Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phaseLeflunomide in the treatment of rheumatoid arthritis.Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells.Methodology and problems of protein-ligand docking: case study of dihydroorotate dehydrogenase, thymidine kinase, and phosphodiesterase 4.Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts.Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.Janus kinase 3: a novel target for selective transplant immunosupression.Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.Anti-peptide immunoglobulins from rabbit and chicken eggs recognise recombinant human dihydroorotate dehydrogenase and a 44-kDa protein from rat liver mitochondria.Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide.Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma.
P2860
Q22242305-AAD3B3A9-0466-4E6D-A6C3-737401E01136Q24673034-14C8C129-2160-4402-A82D-45345751A8A3Q24675005-D2817B22-29D5-4EB5-A2F7-30C234DC2E7EQ26852136-B155FC31-F2CA-424B-8CD9-5B6FDC80515DQ31156888-622D94DC-B07E-40C7-9438-08F2801D231BQ33179243-CF2B204E-6F54-4CB4-A6EA-1427AE0565C4Q33380457-EE12AC23-13E9-4E1B-B5DB-B988CCEA95FCQ33903812-913A8C82-2998-4DCE-8D19-3AAF590E4526Q34066654-C07D96EA-8E40-42D5-84C2-0EF596C629F2Q34345424-3F39372F-04C6-4828-A49F-9E81A2E4AF4FQ34633683-54FBDAEA-6455-40A2-AAD9-C0F713C69D0EQ35518697-12829B0C-6EDC-472B-BBBF-57987822E8B6Q35870244-AB6FF656-C1BF-4475-8450-408D44DE71D0Q36150789-70ADAD42-E3BB-4D75-9109-28B36D5AD5A0Q36181201-8E07A77E-C7F4-405F-B5B6-8DF3FA34A591Q36899427-FB890312-BF85-4336-B146-77C12CA8ED65Q37355946-730A0DDC-E0D7-4DFA-BA1B-972CA52FBB43Q37580399-8C056491-CFAB-42DD-8B46-5B2553EF4C66Q37877256-A0513955-58D6-487A-8E7D-D1BF12F33CB4Q37884434-C37D1A83-591E-4347-875D-5400336810D6Q38175431-B7339955-3152-4046-AF07-3A5B7D797B29Q38216015-E9C6B2D1-C8EE-404C-BD9C-8275A81D6004Q41017180-2FAF3F75-C67A-45BB-A0AB-D970EE18C030Q41721626-A698C4E1-4B9A-4189-8E09-AFBD1510097FQ43061691-A33D9955-064D-467A-91EB-1F2763B0E446Q43513980-CD7C0201-5104-4C8F-B953-A7920F48DA17Q44263319-343C2AA6-3D56-4A45-A2B7-A5D40238B988Q45024320-52FD1B42-1425-44C2-AE47-F6388E1B6CA2Q45029733-13B58218-2159-4C24-9042-4EB7F656E9ACQ45177699-178F1337-508F-4778-87FD-3CAA32F3D945Q46909270-D42DF64D-5CCE-4B50-B5AF-567B5770F138Q47682285-343E5AA5-0AD9-44BD-B612-0E8EA57646B8Q48066009-FB995A92-044F-41B6-AC5E-9D7EBA09EC35Q52035512-C84D156D-9732-49B6-9523-1598A52904FCQ54136937-DBD5F656-E416-4624-B40E-CE5EDC7F7C96
P2860
Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Dihydroorotate dehydrogenase i ...... the immunomodulatory compound.
@ast
Dihydroorotate dehydrogenase i ...... the immunomodulatory compound.
@en
type
label
Dihydroorotate dehydrogenase i ...... the immunomodulatory compound.
@ast
Dihydroorotate dehydrogenase i ...... the immunomodulatory compound.
@en
prefLabel
Dihydroorotate dehydrogenase i ...... the immunomodulatory compound.
@ast
Dihydroorotate dehydrogenase i ...... the immunomodulatory compound.
@en
P2093
P2860
P356
P1476
Dihydroorotate dehydrogenase i ...... the immunomodulatory compound.
@en
P2093
Bruneau JM
Curnock AP
Hambleton AB
Hambleton P
P2860
P304
22467-22472
P356
10.1074/JBC.270.38.22467
P407
P577
1995-09-01T00:00:00Z